MTRI
InMed Pharmaceuticals Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Nov 5 ▲ 1 insider buy $34.6K at $13.10
- Nov 9 FDA: Mentari Therapeutics to Present at Upcoming Investor Confe…
- Nov 9 Trading halt: Halt Resumed: MTRI, trading resumed after LUDP (Volatility…
- Nov 9 Trading halt: Trading Halt: MTRI · LUDP (Volatility Trading Pause)
- Nov 10 InMed Pharmaceuticals completed its reverse merger with Mentari Ther…
- Nov 11 Trading halt: Halt Resumed: MTRI, trading resumed after LUDP (Volatility…
- Nov 11 Trading halt: Trading Halt: MTRI · LUDP (Volatility Trading Pause)
- Nov 16 New report: subscribers see the details Unlock
Signal stack
Where each data set points today.
- InsidersBULLISH
1 insider bought $34.6K at an average $13.10. No open-market sales. Price is 52% above their cost.
- TrendUPTREND
39% above its 50-day average. New closing high $19.87 on Nov 16.
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Shegog Todd Director Nov 9, 2026 | AWARD | 37,000 sh |
Pernice Michelle Patricia Director Nov 9, 2026 | AWARD | 37,000 sh |
Divis Gregory J See Remarks Nov 9, 2026 | AWARD | 1,560,599 sh |
Bruno Julianne Director Nov 9, 2026 | AWARD | 37,000 sh |
Seurer Jerad G. See Remarks Nov 9, 2026 | AWARD | 257,000 sh |
Hagen Brett R See Remarks Nov 9, 2026 | AWARD | 171,000 sh |
Sandler Laura Lee Director Nov 9, 2026 | AWARD | 37,000 sh |
ADAR1 Capital Management, LLC 10%+ Owner Nov 5, 2026 | BUY | $34.6K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | None | None | No data | $0.00 |
| Next Q | None | None | No data | $0.00 |
| Current FY | -$1.75 | -$1.75–-$1.75 | No data | $0.00 |
| Next FY | None | None | No data | $0.00 |
Short side
FINRA| Nov 11, 2026 | Volatility Pause | Resumed |
| Nov 9, 2026 | Volatility Pause | Resumed |
| Nov 9, 2026 | Volatility Pause | Resumed |
| Nov 9, 2026 | Volatility Pause | Resumed |
| Nov 9, 2026 | Volatility Pause | Resumed |
SecBot reports
9 filings · 1 press release · 0 bullish · 1 bearish · 1 mixed · 7 neutral- BEARISH SC 13G/ANov 16, 2026
Squadron Capital Management LLC filed an amended Schedule 13G disclosing a 0.0% stake in InMed Pharmaceuticals Inc. as of September 30, 2026, indicating it has exited its position. This follows the company's reverse merger with Mentari Therapeutics on November 6, 2026, and the $490M pre-closing…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL 8-KNov 16, 2026
Mentari Therapeutics (formerly InMed Pharmaceuticals) filed unaudited financials for the pre-merger entity Mentari for Q3 2026, showing a net loss of $32.2M for the quarter and $63.0M for the nine months ended September 30, 2026, with no revenue and an accumulated deficit of $82.4M. The filing…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13GNov 13, 2026
Commodore Capital LP filed a Schedule 13G disclosing a 5.6% passive stake in Mentari Therapeutics…
Monitor for any future amendments that could signal a shift from passive to active intent, particularly if Commodore Capital engages with management or increases its stake significantly. The…
- NEUTRAL SC 13GNov 13, 2026
Deep Track Capital, LP filed a Schedule 13G disclosing a 5.64% passive stake in Mentari…
Deep Track's new 5.64% passive stake, combined with ADAR1 Capital's 17.2% position, means over 22% of shares are held by two passive filers post-merger. Monitor for any future 13D conversion or…
All MTRI filing & press-release reports (10)
- SC 13G/A reportNov 16, 2026
- 8-K reportNov 16, 2026
- SC 13G reportNov 13, 2026
- SC 13G reportNov 13, 2026
- SC 13D reportNov 12, 2026
- 3 reportNov 12, 2026
- 3 reportNov 12, 2026
- 3 reportNov 12, 2026
- 8-K reportNov 10, 2026
- PRESS-RELEASE reportNov 9, 2026